Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106193 | 0.85 | DRD2 (0.51) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL27682910 | 0.82 | DRD2 (0.49) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL381503 | 0.81 | NOTUM (0.51) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL2224843 | 0.81 | LMNA (0.59) | LMNANOTUMHDAC1HDAC8HDAC6 | |
| SCHEMBL15762228 | 0.81 | HDAC1 (0.50) | LMNANOTUMHDAC1HDAC8HDAC6 | |
| SCHEMBL25012006 | 0.81 | LMNA (0.43) | DRD2DRD4DRD3LMNAGAA | |
| SCHEMBL6593764 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL4826786 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL202789 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3LMNAALDH1A1 | |
| SCHEMBL5544565 | 0.81 | DRD2 (0.54) | DRD2DRD4DRD3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1599452-B1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| EP-1599452-A1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| WO-2004076427-A1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | DRD2 2466/4885DRD4 2790/4885DRD3 1857/4885 |
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | PC, DPP4, FABP3 | DRD2 2063/4885DRD4 1332/4885DRD3 1419/4885 |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | DRD2 43/4885DRD4 92/4885DRD3 97/4885 |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | DRD2 3028/4885DRD4 2642/4885DRD3 2179/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | DRD2 97/4885DRD4 112/4885DRD3 183/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | DRD2 2406/4885DRD4 1875/4885DRD3 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.